Award
National Cancer Institute 5R01CA285726-03
CD200R blockade for cancer immunotherapy
Recipient
Ohio State University
Award Amount
$676,719.00
Ceiling
$676,719.00
Awarded
July 06, 2026
Identifier
5R01CA285726-03
NIH grant awarded to Ohio State University for research on CD200R blockade to enhance cancer immunotherapy by improving immune cell recruitment and T cell function, and exploring combination therapies with angiogenesis inhibitors.
Description
This project aims to test whether CD200R blockade, either genetically or using novel antagonist antibodies, enhances chemokine-mediated immune cell recruitment to tumors and T cell functions in tumors. It also investigates if angiogenesis inhibitors can increase the efficacy of CD200R blockade therapy. The study will evaluate the roles of key chemokines regulated by CD200R signaling in recruiting immune effectors and their roles in tumor angiogenesis, as well as intrinsic roles of CD200R signaling in T cells. The ultimate goal is to develop combination therapies involving CD200R blockade and angiogenesis inhibitors.